study_id,year,design,effect_type,effect_point,ci_low,ci_high,n_treat,n_ctrl,risk_of_bias,doi,journal_id,outcome,population,adverse_events,duration_weeks
LONG-LON01-01,2022,randomized controlled trial,SMD,0.2588,0.0857,0.4319,74,85,low,10.1234/long-lon01-01,longevity-journal-01,cellular_ageing,Adults with cellular ageing concerns,None reported,12
LONG-LON01-02,2013,randomized controlled trial,SMD,0.2534,0.0979,0.4089,87,70,low,10.1234/long-lon01-02,longevity-journal-02,cellular_ageing,Adults with cellular ageing concerns,Transient headache,11
LONG-LON01-03,2018,randomized controlled trial,SMD,0.248,0.11,0.386,70,85,some concerns,10.1234/long-lon01-03,longevity-journal-03,cellular_ageing,Adults with cellular ageing concerns,Mild GI discomfort,9
